Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patientsShow others and affiliations
2018 (English)In: Schizophrenia Research, ISSN 0920-9964, E-ISSN 1573-2509, Vol. 199, p. 438-441Article in journal, Letter (Other academic) Published
Abstract [en]
n/a
Place, publisher, year, edition, pages
Elsevier, 2018. Vol. 199, p. 438-441
Keywords [en]
Schizophrenia; Sphingolipids; Cerebrospinal fluid; Biomarkers; Demyelination
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:liu:diva-151950DOI: 10.1016/j.schres.2018.03.029ISI: 000444845900070PubMedID: 29627172Scopus ID: 2-s2.0-85053468791OAI: oai:DiVA.org:liu-151950DiVA, id: diva2:1256333
Note
Funding Agencies|Swedish Medical Research Council [2009-7053, 2013-2838, 523-2014-3467, 2015-02836]; Thematic Center in Inflammation at the Karolinska Institute, the Vinnova (CIDaT); Swedish Brain Foundation; Ahlen-siftelsen; Petrus och Augusta Hedlunds Stiftelse; Torsten Soderbergs Stiftelse; AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science; Soderbergs Konigska Stiftelse; Stockholm County Council (ALF); Stockholm County Council (PPG); Karolinska Institutet
2018-10-162018-10-162018-10-24Bibliographically approved